Multiple Myeloma Stocks List

Recent Signals

Date Stock Signal Type
2021-05-14 ADAP Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-14 ADAP Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 BMY Cup with Handle Other
2021-05-14 BMY Fell Below 20 DMA Bearish
2021-05-14 CALA MACD Bullish Signal Line Cross Bullish
2021-05-14 CASI NR7 Range Contraction
2021-05-14 CASI Narrow Range Bar Range Contraction
2021-05-14 CGEN 20 DMA Resistance Bearish
2021-05-14 CLLS Bullish Engulfing Bullish
2021-05-14 CLLS Slingshot Bearish Bearish Swing Setup
2021-05-14 CNST Slingshot Bearish Bearish Swing Setup
2021-05-14 CNST MACD Bullish Signal Line Cross Bullish
2021-05-14 CRIS Boomer Buy Setup Bullish Swing Setup
2021-05-14 CRIS 1,2,3 Pullback Bullish Bullish Swing Setup
2021-05-14 CRIS Upper Bollinger Band Walk Strength
2021-05-14 CRIS Calm After Storm Range Contraction
2021-05-14 CRIS Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-14 GMAB Bollinger Band Squeeze Range Contraction
2021-05-14 GMAB Crossed Above 200 DMA Bullish
2021-05-14 HARP MACD Bearish Centerline Cross Bearish
2021-05-14 IMGN Lower Bollinger Band Walk Weakness
2021-05-14 NEXI Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-14 NEXI Narrow Range Bar Range Contraction
2021-05-14 PSTV NR7 Range Contraction
2021-05-14 PSTV Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 PSTV Stochastic Buy Signal Bullish
2021-05-14 PSTV Narrow Range Bar Range Contraction
2021-05-14 PSTV NR7-2 Range Contraction
2021-05-14 STRO NR7 Range Contraction
2021-05-14 STRO Bollinger Band Squeeze Range Contraction
2021-05-14 STRO 20 DMA Resistance Bearish
2021-05-14 XOMA Stochastic Buy Signal Bullish
2021-05-14 XOMA Slingshot Bearish Bearish Swing Setup
2021-05-14 XOMA Lower Bollinger Band Walk Weakness
2021-05-14 XTLB 50 DMA Resistance Bearish
2021-05-14 XTLB 20 DMA Resistance Bearish

Recent News for Multiple Myeloma Stocks

Date Stock Title
May 16 BMY Wall Street Breakfast: The Week Ahead
May 16 BMY 4 Surefire Value Stocks to Buy for a Biden Bull Market
May 16 BMY Bristol Myers’ mavacamten improves health status in patients with obstructive hypertrophic cardiomyopathy
May 15 BMY Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology’s 70th Annual Scientific Session
May 15 BMY The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
May 14 BMY ARK Investment's Top 5 New Buys in the 1st Quarter
May 14 STRO Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
May 14 BMY 2 Top Healthcare Stocks for 2021 and Beyond
May 14 BMY Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
May 14 CGEN Compugen Ltd. (CGEN) Q1 2021 Earnings Call Transcript
May 13 CRIS Why Curis Stock Crashed on Thursday
May 13 CGEN Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2021 Results - Earnings Call Transcript
May 13 CRIS Impressive Data for Cancer Drug Gives Curis Stock More Room to Run
May 13 CGEN Why Compugen Stock Is Jumping Today
May 13 CRIS Curis Stock Is On A Wild Ride — What Spooked Investors After A 65% Surge
May 13 CASI CASI Pharmaceuticals: Q1 Earnings Insights
May 13 CASI CASI Pharmaceuticals EPS misses by $0.05, beats on revenue
May 13 CGEN Compugen EPS beats by $0.01
May 13 CGEN Compugen Reports First Quarter 2021 Results
May 13 CASI CASI Pharmaceuticals Announces First Quarter 2021 Financial Results

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Often, no symptoms are noticed initially. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloidosis.The cause is unknown. Risk factors include obesity, radiation exposure, family history, and certain chemicals. The underlying mechanism involves abnormal plasma cells producing abnormal antibodies which can cause kidney problems and overly thick blood. The plasma cells can also form a mass in the bone marrow or soft tissue. When only one mass is present, it is known as a plasmacytoma, while more than one is known as multiple myeloma. Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. Another common finding is high blood calcium levels.Multiple myeloma is considered treatable, but generally incurable. Remissions may be brought about with steroids, chemotherapy, targeted therapy, and stem cell transplant. Bisphosphonates and radiation therapy are sometimes used to reduce pain from bone lesions.Globally, multiple myeloma affected 488,000 people and resulted in 101,100 deaths in 2015. In the United States, it develops in 6.5 per 100,000 people per year and 0.7% of people are affected at some point in their lives. It usually occurs around the age of 61 and is more common in men than women. It is uncommon before the age of 40. Without treatment, typical survival is seven months. With current treatments, survival is usually 4–5 years. This gives a five-year survival rate around 49%. The word myeloma is from the Greek myelo- meaning "marrow" and -oma meaning "tumor".

More about Multiple Myeloma
Browse All Tags